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Abstract
Background: Head and neck cancers are of particular interest to health care providers, their patients, and those
paying for health care services, because they have a high morbidity, they are extremely expensive to treat, and of
the survivors only 48% return to work. Consequently the economic burden of oral cavity, oral pharyngeal, and
salivary gland cancer (OC/OP/SG) must be understood. The cost of these cancers in the U.S. has not been
investigated.
Methods: A retrospective analysis of administrative claims data for 6,812 OC/OP/SG cancer patients was undertaken.
Total annual health care spending for OC/OP/SG cancer patients was compared to similar patients without
OC/OP/SG cancer using propensity score matching for enrollees in commercial insurance, Medicare, and Medicaid.
Indirect costs, as measured by short term disability days were compared for employed patients.
Results: Total annual health care spending for OC/OP/SG patients during the year after the index diagnosis was
$79,151 for the Commercial population. Health care costs were higher for OC/OP/SG cancer patients with
Commercial Insurance ($71,732, n = 3,918), Medicare ($35,890, n = 2,303) and Medicaid ($44,541, n = 585) than the
comparison group (all p< 0.01). Commercially-insured employees with cancer (n = 281) had 44.9 more short-term
disability days than comparison employees (p< 0.01). Multimodality treatment was twice the cost of single modality
therapy. Those patients receiving all three treatments (surgery, radiation, and chemotherapy) had the highest costs
of cost of care, from $96,520 in the Medicare population to $153,892 in the Commercial population.
Conclusions: In the U.S., the cost of OC/OP/SG cancer is significant and may be the most costly cancer to treat in
the U.S. The results of this analysis provide useful information to health care providers and decision makers in
understanding the economic burden of head and neck cancer. Additionally, this cost information will greatly assist
in determining the cost-effectiveness of new technologies and early detection systems. Earlier identification of
cancers by patients and providers may potentially decrease health care costs, morbidity and mortality.
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Background
Health care costs for patients; employers, and health
care plans are rising in the U.S. [1,2]. Thus, methods for
decreasing health care expenditures are being rigorously
scrutinized. Cancer diagnosis and treatment contributes
significantly to these costs [3-6]. Head and neck cancers
are of particular interest because they are extremely
expensive to treat, have a high morbidity, and of those
individuals that survive only 48% return to work [7].
Further, recent evidence suggests that patients with
cancer are at a particular risk for bankruptcy [8]. To
minimize cost and risk, employers are grappling with
enacting programs such as banning smoking on the
work property, supporting smoking cessation programs,
and making health care benefit decisions on new early
detection and screening tools [9].
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arise from five primary sites (larynx, pharynx, oral cavity,
salivary glands and paranasal sinuses). Cancers arising
from three of the sites or subsites (oral cavity, oral phar-
ynx and salivary gland tumors – OC/OP/SG) present
with symptoms that may prompt a visit to an oral health
provider, thus these cancers are the focus of this analysis.
Known risk factors for oral and oropharyngeal cancers
include cigarette smoking, chewing tobacco and alcohol
consumption [10]. Human Papilloma Virus (HPV) has
recently been implicated as a causal factor for oropha-
ryngeal cancers and now accounts for 40 to 60% of cases
[10-12]. HPV associated tumors tend to occur in younger
patients lacking the traditional risk factors of tobacco
and alcohol use. The incidence of oropharynx cancers is
rising rapidly [13] as is the incidence of oral tongue
lesions in younger adults and women [14]. Salivary gland
tumors are a relatively rare group of tumors that behave
in a heterogeneous manner; and although they are un-
common, they result in substantial morbidity.
Treatment for individuals with OC/OP/SG cancers
includes surgery, radiation therapy and chemotherapy [15].
Each treatment modality is associated with distinct acute
and late treatment effects. With advances in surgical tech-
niques, particularly in the field of reconstruction, the func-
tional and cosmetic outcomes for individuals undergoing
primary surgical resection may be excellent, even for those
patients with large tumors. However, cancer surgery can
still result in substantial functional impairment and disfig-
urement. Radiation therapy is also associated with severe
acute and late affects. Common acute toxicities include
xerostomia, painful mucositis, dermatitis, and severe dys-
phagia which may require feeding tube placement. Late
radiation effects include neck and shoulder fibrosis and
edema, trismus, mucosal sensitivity, late effect xerostomia
and dental caries with associated dental loss [16]. When
used in combination with chemotherapy, these effects may
be exacerbated. It should be noted that head and neck can-
cer is associated with a high rate of mood disorders includ-
ing anxiety and depression and higher rates of depression
have been observed in individuals with tumor and treat-
ment related disfigurement [17].
In general, the more advanced stage the cancer at diag-
nosis, the worse the prognosis. For example, the overall
five-year survival rate is approximately 60% for all stages
of oral cancer patients in the U.S., but survival increases
to 83% when the cancer is detected in its early stage
[18]. Unfortunately, most patients are diagnosed with
locally advanced disease. Only 36% - 41% of oral cavity/
oral pharyngeal cancers are detected early [18]. In
addition to improving survival, early detection of OC/
OP/SG cancers may identify early stage disease which
requires less aggressive and less toxic therapies. Thus,
for OC/OP/SG cancers screening and early detectionhave become an important focus for health care provi-
ders. New early detection and screening tools are being
developed in the hopes of increasing the rate of early
cancer diagnosis [9]. By including screening as part of
regular dental exams, dentists and hygienists have the
opportunity to detect these cancers early, decreasing
morbidity and mortality. Additionally, educational pro-
grams to raise awareness among health care providers
and programs instructing individuals on self-examination
may result in earlier detection and greatly reduce the
high cost and mortality of OC/OP/SG cancers.
It may be hypothesized that early detection of cancers
may diminish the cost of care for individuals and
employers, thus providing additional impetus for more
effective screening efforts. Despite the prevalence of OC/
OP/SG cancers and the potential for disability and disfig-
urement that may result from treatment, previous re-
search on the direct and indirect cost burden is limited.
Most of the research has focused on the broader cat-
egory of head and neck cancers [3,5,19]. To our know-
ledge, a comprehensive study of the direct and indirect
cost burden of these cancers among relatively large sam-
ples of Medicare, Medicaid and commercially insured
patients has not been conducted. To fill this gap in
knowledge, we conducted a study to determine the direct
costs of OC/OP/SG cancers during the first year after
diagnosis. We examined three cohorts of individuals:
Commercially-insured enrollees, enrollees with Medicare
and supplemental benefits from their employer, and
Medicaid beneficiaries. For employees within the Com-
mercially-insured sample, we calculated the indirect costs
of oral or pharyngeal cancer as measured by short term
disability costs. We also estimated spending by treatment
modality (e.g., surgery, radiation or combined treatment)
and examined patterns in spending over time from six
months to three years after the oral cavity, oral pharynx
and salivary gland (OC/OP/SG) cancer diagnosis.
Methods
Study design
We conducted a retrospective, observational study of the
direct and indirect cost burden of OC/OP/SG cancer
using the health care experiences of employees and their
dependents with employer- sponsored health insurance
(Commercial), retirees and their dependents with Medi-
care Supplemental coverage from their former employer,
and Medicaid beneficiaries in 11 states. To calculate the
cost burden of illness within each payer, a comparison
group of individuals without OC/OP/SG cancer was cre-
ated using propensity scoring techniques matching
people based on their socio-demographic characteristics
(e.g., plan type, year of diagnosis) and health status. The
cost burden of illness for OC/OP/SG cancer was then
estimated by comparing spending for cases with OC/OP/
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Data sources
Data for this study were obtained from the 2004–2008
Thomson Reuters MarketScanW Databases: Commercial
Claims and Encounters Database (CCAE), Medicare Sup-
plemental and Coordination of Benefits Database, Medic-
aid Multi-State Database and the Health Productivity and
Management (HPM) Database.
The CCAE database contains the enrollment and
health care (medical and drug) claims experience of sev-
eral million employees and their dependents that are
covered annually under a variety of health plans offered
by medium-sized and large firms. The MarketScan
Medicare Supplemental Database contains the enroll-
ment and health care claims of millions of individuals
with Medicare supplemental insurance paid for by
employers. Both the Medicare-covered portion of pay-
ment (represented as Coordination of Benefits Amount,
or COB) and the employer-paid portion are included in
this database. The MarketScan Medicaid Multi-State
Database comprises data from 11 contributing geo-
graphically disperse states and contains the administra-
tive claims experience of millions of Medicaid enrollees
(e.g., over 5 million enrollees in 2007). The CCAE,
Medicare Supplemental, and Medicaid databases all
include inpatient, outpatient, emergency room and out-
patient prescription drug claims, linked by a unique pa-
tient identifier, except for outpatient prescription drugs
in the Medicaid database for which there is no data. The
Medicaid database has all claims, except for outpatient
prescription drug claims for the small share of enrollees
who were dually eligible for Medicare (6% of Medicaid
sample with OC/OP/SG cancer). For Commercially
insured patients, switching from one health plan to an-
other within a single employer did not constitute disenroll-
ment. Data from all carve-out plans (e.g., prescription
drug, mental health) were also included in the database.
Finally, the MarketScan HPM Database is linkable via a
unique enrollee identifier to the medical and pharmacy
experience of a subset of employees in the CCAE database
whose employers contribute their short-term disability
claims experience.
The data conformed to the Health Insurance Portability
and Accountability Act of 1996 (HIPAA) confidentiality
requirements, so neither informed consent nor Institu-
tional Review Board (IRB) approval were necessary for this
study.
Patients with oral cavity, oral pharynx or salivary gland
cancers
OC/OP/SG cancer patients were identified via at least one
inpatient claim with an International Classification ofDisease, 9th Revision, Clinical Modification (ICD-9-CM)
code for oral cavity, oral pharynx, or salivary gland cancer:
ICD-9-CM codes 141.0-141.9 (base of tongue), 142.0-142.9
(major salivary gland), 143.0-143.9 (gum), 144.0-144.9
(floor of mouth), 145.0-145.9 (other sites of mouth), 146.0-
146.9 (oropharynx), 149.0-149.9 (other lip, oral cavity and
pharynx) or two outpatient claims with an ICD-9-CM code
for OC/OP cancer for an office visit and/or emergency
department visit that were at least 30 days apart. The sec-
ond outpatient claim was required to confirm the first diag-
nosis and ensure that patients had active disease, as
reflected by utilization of medical services. The service date
of the first observed claim with a diagnosis of OC/OP/SG
cancer must have occurred between 2005 and 2007 and
this date was designated as the index date. Patients must
have been continuously enrolled for at least 6 months be-
fore and 6 months after the index date. However, the pri-
mary analysis only considered patients with at least 1 year
of follow-up after the index date. A secondary analysis
examined results for cohorts of patients with varying
lengths of follow-up (from 6 months to 3 years). Only
patients age 18 and older were included in the study.
The focus of the study was to track cost for patients at
the start of a new episode of care for an OC/OP/SG can-
cer. Patients were excluded if they had a diagnosis of OC/
OP/SG cancer any time in the 6 month pre-index period.
A total of 3,918 patients in the CCAE, 2,306 patients in
the Medicare Supplemental and 588 patients in the Medic-
aid database met the criteria for inclusion in this study.
Three patients from the Medicare Supplemental Database
and three from the Medicaid Database were excluded be-
cause they were extreme outliers compared to the rest of
OC/OP/SG cancer patients (>$800,000 total costs for
Medicare And> $1,000,000 for Medicaid).
Companies supplying short-term disability data in
addition to medical claims information were a subset of
those contributing medical claims data. Short-term dis-
ability information was collected only for employees and
was not available for spouses or dependents. Of the
Commercially-insured OC/OP/SG cancer patients, 281
had short-term disability information.
Comparison group and propensity score matching
We created matched comparison groups for the primary
cohort of OC/OP/SG cancer patients who could be fol-
lowed for at least 1 year after their index diagnosis. Separ-
ate comparison groups were created for each payer group
(Commercial, Medicare Supplemental, and Medicaid). To
construct the comparison group, all enrollees who were at
least 18 years old and had at least 18 months of continu-
ous medical and prescription drug enrollment with none
of the ICD-9-CM codes listed above within each database
were selected. The enrollees meeting these criteria were
randomly assigned an index date so the distribution of
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those with OC/OP/SG cancer. All comparison group
members must have been continuously enrolled for
6 months before and 1 year after their assigned index date
to match the enrollment requirements for the main ana-
lysis of 1 year post- index costs.
A propensity score was estimated for each OC/OP/SG
cancer patient and comparison group member using lo-
gistic regression models to predict the likelihood of hav-
ing OC/OP/SG cancer, as a function of socio-
demographic characteristics, plan type, health status and
year of index date (described below). Separate regres-
sions were estimated for each data source (Commercial,
Medicare, and HPM). For each payer sample, we
matched by subgroups based on the site of the index
OC/OP/SG cancer diagnosis. The predicted value of the
dependent variable from the logistic regression (i.e., the
predicted probability of having OC/OP/SG cancer) was
the propensity score assigned to each patient.
One-to-one matching of comparison patients to employ-
ees with cancer was then performed within each of the
groups, based on the value of the propensity score, using a
greedy matching algorithm [20]. This produced matched
sets of patients and comparison group members chosen
from a large population who had similar demographic,
plan type, location, and health status characteristics.
Patient characteristics
We matched on the following socio-demographic vari-
ables that are well-known determinants of health care
utilization and expenditures: age, gender, U.S. Census re-
gion and whether the enrollee’s residence was in an
urban or rural area. In addition, we also matched on
some employee characteristics available for the CCAE
and Medicare samples: relationship (employee or
spouse/child/dependent) and classification (active full
time vs. other). Median income and percent of college
graduates (among residents aged 25 years and older) of
the enrollee’s ZIP code from the 2000 Census were
included as a proxy for socio-economic status.
The matching regression also included insurance plan
type. For Medicare and CCAE, the following plan types
were included in the sample: indemnity plan, exclusive
provider organization/point of service plan (EPO/POS),
preferred provider organization (PPO), health mainten-
ance organization (HMO), or capitated point of service
plan (Capitated POS). Data on health plan type were
missing for some employees and this was accounted for
in the statistical models. The matching regression also
controlled for Medicaid eligibility category and an indi-
cator for dual eligibility for Medicaid and Medicare.
Pre-diagnosis health status was measured by the Charl-
son Comorbidity Index (CCI), a numeric scale reflecting
the risk of death or serious disability in the next year basedon the presence of a diagnosis for one of 19 conditions in
the 6 month pre-period [21]. We created another measure
of health status by modifying the CCI to exclude cancer
diagnoses and other diagnoses related to risk factors for
OC/OP/SG cancers (excluded any malignancy, metastatic
solid tumor and chronic pulmonary disease). By using the
modified CCI for matching, we were able to obtain a
matched comparison group that had a similar number of
other comorbidities as patients with OC/OP/SG cancer.
Since the CCI does not encompass mental health comor-
bidities, a count of the number of Psychiatric Diagnosis
Groups (PDGs) contained in the patient’s claims history in
the 6 month pre-period was also included. There are 11
PDGs, representing the mental health burden of each
enrollee [22]. Examples include organic mental disorders,
substance use disorders, depression, and bipolar disorder.
The year of the index date was also included in the
propensity score equation to represent trends in diagno-
sis, treatment, or medical spending.
Outcome variables
Expenditures
The primary outcomes for this study were direct medical
expenditures and indirect (short-term disability) expendi-
tures during the year following the index date. Direct health
care expenditures were measured as allowed charges for in-
patient admissions, outpatient hospital visits, office visits,
emergency department visits, and outpatient prescription
drugs. All sources of payment were included in the meas-
ure of health care expenditures, including payments from
the employer, plan, patient (e.g. copayments and deduct-
ible), Medicare, if eligible, and any coordination of benefits
(other payers) payments. All dollar metrics were adjusted
to year 2009 values using the Consumer Price Index Infla-
tion Calculator from the Bureau of Labor Statistics [23].
Short term disability
Short-term disability (STD) was recorded as the number
of days with short term disability benefits. These hours
were converted to costs using an hourly rate of $29.37
representing compensation from civilian workers. This
category of civilian workers includes private industry
employees in addition to state and local workers. Since
STD benefits typically do not replace full wages, the
value for each STD day was set at a level of 70% com-
pensation [24]. For example, an enrollee with 5 days of
STD would have STD costs of 5 days*70% compensa-
tion*$29.37 per hour*8 h per day = $822.36.
Analysis of spending patterns
Cost burden of illness for oral cavity or oral pharynx or
salivary gland cancer
Descriptive statistics were calculated for patients with
OC/OP/SG cancer and their matched comparison group
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student’s t-tests for continuous variables and Pearson
chi-square tests for categorical variables. The cost bur-
den of OC/OP/SG cancer was calculated as the differ-
ence in direct or indirect expenditures between cases
with OC/OP/SG cancer and their matched comparison
group during the year after the index date. Student’s t-
tests were used to assess the statistical significance of
these differences.
Spending by treatment modality
To proxy for cancer staging (severity), treatment modality
(surgery only, radiation only, chemotherapy only, the com-
binations the three modalities or no known treatment) was
measured by assessing each patient’s claims for specific
HCPCS, CPT-4 and ICD-9-CM procedure codes as well as
drug codes for chemotherapy (any antineoplastic drugs) in
the year after the index date (Additional file 1).
Time trends in spending
Since the cause of disenrollment was not observed and
mortality rates are non-negligible, we formed cohorts
with varying lengths of time of enrollment to determine
the costs of survivorship within the plan. To do so, four
cohorts of cancer patients were created based on the
length of enrollment. Each cohort could be followed over
different time frames:
 (6 month cohort) enrolled at least 6 months after
the index date but less than 12 months,
 (1 year cohort) enrolled at least 12 months after the
index date but less than 24 months,
 (2 year cohort) enrolled at least 24 months after the
index date but less than 36 months,
 (3 year cohort) enrolled at least 36 months after the
index date.
Direct costs in 6 month intervals were created for each
cohort of patients (6 month, 1 year, 2 year and 3 year as
enrollment allowed) and plotted in a graph. SAS 9.2 was




The Commercial and Medicare samples were drawn from
similar populations (employees and their dependents in
self-insured plans), and they were largely similar except for
age and retirement status. In the Commercial sample, indi-
viduals with OC/OP/SG cancer (N=3,918) were on aver-
age 53.4 years old and 68.7% were male (Table 1).
Medicare patients were older (average age 74.5 years) and
the sample included more men than women (65.4% male).
Individuals with OC/OP/SG cancer in the Commercialand Medicare samples were more likely to live in urban
areas (81.7% Commercial, 81.3% Medicare). Approxi-
mately half of the Commercially insured OC/OP/SG can-
cer individuals were active, full time employees and more
than half had health care coverage under a preferred pro-
vider organization (56.0%). The Medicare sample included
retirees who were no longer working and 61.4% were
enrolled in a comprehensive insurance plan type. After
propensity score matching, characteristics of individuals
with OC/OP/SG cancer were similar to the matched com-
parison group. The Medicaid sample was smaller than the
other samples and included 585 patients with OC/OP/SG
cancer who were on average 53.4 years old. The Medicaid
sample had a higher burden of comorbid conditions, as
indicated by a higher Charlson Comorbidity Index and a
larger number of Psychiatric Diagnosis Groups.
Cost burden of oral cavity, oral pharynx, or salivary gland
cancer
For the Commercial sample, total annual health care
spending during the year after the index diagnosis was
$79,151 (std.dev. $86,170) for individuals with OC/OP/SG
cancer, compared with $7,419 (std.dev. $22,665) for the
comparison group; the difference of $71,732 (p< 0.001)
representing the cost burden of oral cancer (Table 2 and
Figure 1). Total annual health care spending in the Medi-
care Supplemental sample was $48,410 (std.dev. $61,599),
which was $35,890 higher than the comparison group
(p< 0.001).
Employers on average paid 94% ($74,594, std. dev.
$85,023) of the total annual health care spending for
individuals with OC/OP/SG cancer enrolled in Commer-
cial plans (Figure 2). For these individuals, the employer
share of the cost burden of OC/OP/SG cancer was
$68,394 (p< 0.001). In the Medicare Supplemental sam-
ple, Medicare is the primary payer. Consequently, the
employer’s share of total health care costs was substan-
tially lower, although still sizeable ($13,384, std. dev.
$23,742), representing about 28% of total health care
costs. The employer’s share of the cost burden in the
Medicare Supplemental sample was $9,030 (p< 0.001).
Outpatient care accounted for the largest share of em-
ployer costs for both the Commercial sample ($51,307 or
68.8% of employer costs) and Medicare sample ($7,757
or 58.2% of employer costs), shown in Figure 2. Total an-
nual health care expenditures in the Medicaid sample
was $59,404 (std. dev. $74,919) for patients with OC/
OP/SG cancer, which was $44,541 higher than the
matched comparison group.
Treatment modality and health status
Multiple modalities of treatment were more common
than single modality treatment (Table 3). Forty-five per-
cent of the Commercial sample received multimodal
Table 1 Characteristics of patients with OC/OP/SG cancer and matched comparison group

















Number of patients 3,918 3,918 2,303 2,303 585 585
Age in Years 53.42 52.77 <0.001 74.51 74.34 0.392 53.36 52.52 0.148
Age Group
18-34 3.2 3.6 0.643 0.0 0.0 0.673 3.8 4.8 0.776
35-44 8.9 8.8 0.0 0.0 9.9 8.7
45-54 34.9 34.1 0.2 0.4 36.6 37.9
55-64 53.0 53.5 1.2 1.4 43.8 43.6
65-74 0.0 0.0 52.3 51.8 4.3 3.1
75-84 0.0 0.0 37.6 37.7 1.5 1.2
85+ 0.0 0.0 8.7 8.7 0.2 0.7
Gender
Male 68.7 69.3 0.574 65.4 64.6 0.557 58.8 58.1 0.813
Female 31.3 30.7 34.6 35.4 41.2 41.9
Urbanicity
Urban 81.7 82.5 0.471 81.3 82.6 0.489 67.2 67.5 0.604
Rural 17.7 17.1 18.4 17.1 32.6 32.5
Missing 0.6 0.4 0.3 0.3 0.2 0
Geographic Region
Northeast 12.1 12.5 0.392 9.6 9.7 0.191 n.a
Northcentral 26.1 27.6 38.2 41.5
South 44.6 43.8 32.8 31.0
West 16.6 15.6 19.1 17.5
Unknown 0.6 0.5 0.3 0.3
Employee Relationship
Employee 69.5 69.6 0.006 78.6 79.5 0.208 n.a
Spouse 29.8 28.9 21.2 20.4
Child/dependent 0.7 1.5 0.2 0.0
Employee Classification
Salaried/Hourly
Salary 19.4 20.8 0.003 23.4 23.8 n.a
Hourly 23.3 25.7 38.2 37.9
Unknown/missing 57.4 53.5 38.4 38.4
Union/non-union
Union 22.3 25.6 <0.001 40.9 40.3 0.278 n.a
Non-union 33.4 34.7 34.7 36.8
Unknown/missing 44.3 39.7 24.4 22.9
Employment
Active, full time 50.1 50.1 <0.001 1.5 1.4 0.131 n.a
Active, part
time/seasonal
0.9 0.8 0.0 0.0
Retire 23.4 27.2 90.7 88.9
Other/unknown/missing 25.7 21.9 7.8 9.6
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Table 1 Characteristics of patients with OC/OP/SG cancer and matched comparison group (Continued)
Insurance Plan Type
Comprehensive/FFS 11.6 11.5 0.522 61.4 62.7 0.540 64.4 63.2 0.671
EPO 0.6 0.5 0.0 0.0 35.6 36.8
HMO/Managed Care 16.3 15.8 7.7 8.0
POS 11.2 11.6 1.9 1.6
PPO 56.0 55.9 27.5 25.7
POS with capitation 1.3 1.7 0.0 0.0
CDHP 1.9 2.1 0.1 0.3
Missing 1.2 0.9 1.4 1.7
Year of Index Date
2005 40.6 42.7 0.155 45.5 47.7 0.225 54.5 56.1 0.739
2006 32.6 31.1 30.0 29.8 26.7 26.8
2007 26.8 26.2 24.4 22.5 18.8 17.1
Charlson Comorbidity
Index (CCI)
1.67 0.31 <0.001 1.88 0.73 <0.001 2.31 0.81 <0.001
Modified CCIB 0.21 0.20 0.2457 0.47 0.43 0.1303 0.59 0.56 0.6345




$48,710 $48,799 0.828 $46,118 $46,708 0.128 $33,305 $32,782 0.405
Fraction College
Graduates in ZIP
0.26 0.26 0.23 0.24 0.16 0.16 0.834
Race/Ethnicity n.a n.a




Medicaid Eligibility n.a n.a
Blinded/Disabled 82.1 82.4 0.957
Aged 4.3 3.9
Other 13.7 13.7
Medicare Eligibility n.a n.a
Yes 6.0 5.5 0.706
No 94.0 94.5
For sample with 1 year of follow-up in the Medical care data.
Notes
A. P-value from test of the significance of difference between the OC/OP cancer group and matched comparison group.
B. Modified CCI recalculates the CCI excluding tobacco and cancer related diagnoses.
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of patients had unknown therapy (did not have claims for
any of the therapies). In Medicare, 40.6% had multimodal
therapy, 36.6% had single modality therapy, and 22.8% had
unknown therapy. In the Commercial population, the
most common combined therapy was surgery plus either
radiation (17.1%) or surgery plus radiation and chemother-
apy (17.4%). In the Medicare population, surgery plus
radiation (18.8%) was the most frequent multiple modal-
ity therapy, followed by surgery plus radiation andchemotherapy (12.2%). For patients receiving single mo-
dality therapy, surgery predominated in both the com-
mercial (22.5%) and Medicare (28.7%) populations.
About one third (34.9%) of Medicaid patients did not
receive known therapy and the most common therapy
was surgery (15.9%), followed by radiation combined
with chemotherapy (12.0%) and surgery combined with
both radiation and chemotherapy (11.6%).
The pre-diagnosis Charlson Comorbidity Index
(CCI), the Modified CCI (cancer and tobacco related
Table 2 Mean payments, standard deviation, and cost burden, by payer and population





Number of enrollees 3,918 3,918
Total Payments, $ 79,151 7,419 71,732 <0.001
(6,170) (22,665)
Employer Payments, $ 74,594 6,200 68,394 <0.001
(85,023) (20,046)
Out of pocket payments, $ 2,962 829 2,133 <0.001
(4,990) (1,211)
Third Party Payments,$ 1,595 390 1,205 <0.001
(12,915) (6,160)
MEDICARED
Number of enrollees 2,303 2,303
Total Payments, $ 48,410 12,520 35,890 <0.001
(61,599) (27,947)
Employer Payments, $ 13,384 4,354 9,030 <0.001
(23,742) (12,513)
Out of pocket payments, $ 1,747 962 785 <0.001
(3,068) (966)
Medicare and Third Party Payments, $E 33,279 7,204 26,075 <0.001
(53,223) (23,036)
MEDICAIDF
Number of enrollees 585 585
Total Payments, $ 59,404 14,863 44,541 <0.001
(74,919) (28,432)
Standard deviation in parentheses.
For sample with 1 year of follow-up.
Medical and drug expenditures were adjusted to 2009 dollars using Medical Care CPI.
Notes
A: The Cost Burden is calculated as the difference between the mean values for the OC/OP cancer and matched comparison group.
B: The p-value is from a test of statistically significant difference between the OC/OP cancer and comparison group.
C: 6 Patients with a total medical costs exceeding $800,000 in the Commercial database were flagged as outliers, and were excluded before the matching.
D: 9 Patients with a total medical costs exceeding $800,000 in the Medicare database were flagged as outliers, and were excluded before the matching.
E: In the Medicare sample, third party payments or coordination of benefits are primarily Medicare payments, since Medicare pays first of all of the insurance plans
that cover an employee. In the Commercial sample, third party payments may come from a variety of sources, such as benefits from a spouse.
F: 3 Patients with total medical costs exceeding $1,000,000 in the Medicaid database were flagged as outliers, and were excluded before the matching.
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atric Diagnosis Groups (PDGs) varied with treatment
modalities (all p< 0.001), except for the number of
PDGs in the Medicaid sample (p = 0.536). In the Com-
mercial sample, the chemotherapy group had the high-
est average CCI (3.40), Modified CCI (0.43) and
highest count of PDGs (0.21). Radiation and combined
radiation and therapy groups had the highest CCI in
the Medicare sample (2.88) and a relatively high modi-
fied CCI (0.53 and 0.52), but not the highest Modified
CCI in the Medicare sample (0.58, combined surgery
and radiation).Costs by treatment modality
Figure 3 demonstrates the higher average cost of late-
stage multiple modality cancers compared to early stage
single modality treatment. Although information on
stage was not available, the use of single modality ther-
apy was used as a surrogate indicator of early stage dis-
ease and combined modality treatment was used to
represent patients with more advanced disease based
upon the general association between severity and the
use of more aggressive multimodal therapies [25]. Re-
gardless of the type of insurance, multimodal therapy

























Figure 1 Total costs by payer during year after oral/pharyngeal cancer diagnosis. Notes: For sample with 1 year of follow-up. Medical
and drug expenditures were adjusted to 2009 dollars using Medical Care CPI. The Cost Burden is calculated as the difference between the mean
values for the OC/OP/SG cancer and matched comparison group. The p-value is from a test of statistically significant difference between the OC/
OP/SG cancer and comparison group.
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p= 0.132 for Medicaid). Those receiving all three treat-
ments (surgery, radiation, and chemotherapy) had the
highest cost of care, ranging from $96,520 in the Medi-
care population to $153,892 in the Commercial popula-
tion (Table 4). The highest cost single modality therapy
was radiation alone at $66,670 in the Medicare popula-
tion and $105,422 in the Commercial population.
Time trends in spending
As a secondary analysis, we calculated spending trends in
6-month intervals for all of the payer groups starting in
the 6 months before diagnosis and continuing through
three years, as enrollment allowed. Spending trends fol-
lowed a similar pattern across all payer groups with lower
spending in the 6 months preceding the index diagnosisFigure 2 Employer costs by service type, for Commercial Insurance an
Medical and drug expenditures were adjusted to 2009 dollars using Medica
mean values for the OC/OP/SG cancer and matched comparison group. Th
the OC/OP/SG cancer and comparison group.date, followed by a spike in spending in the 6 months fol-
lowing diagnosis (Figures 4, 5, 6). After this spike, spending
levels declined and stayed relatively stable in the next few
years, but did not return to pre-diagnosis levels.
When analyzing time trends by cohort, in the Commer-
cial and Medicare samples the cohort with at least 1 year
but less than 24 months of post-index enrollment had the
highest spending levels. For the Medicaid sample, the
cohort with at least 6 months but less than 12 months of
enrollment had the highest spending levels. As the cohort
longevity increased (from 6 months to 3 years), costs
tended to be lower.
Short-term disability
Patients included in the indirect cost (short term disability)
analysis were commercially insured employees (n= 281).d Medicare Enrollees. Notes: For sample with 1 year of follow-up.
l Care CPI. The Cost Burden is calculated as the difference between the
e p-value is from a test of statistically significant difference between


















Number of Patients 3918 233 882 77 361 55 670 681 2959 959
Percent of oral cancer group 100.0% 5.9% 22.5% 2.0% 9.2% 1.4% 17.1% 17.4% 75.5% 24.5%
Charlson Comorbidity 1.67 2.54 0.80 3.40 3.15 2.20 1.80 2.19 1.86 1.06 <0.001
Index (CCI)
Modified CCIC 0.21 0.29 0.21 0.43 0.24 0.25 0.27 0.18 0.23 0.15 <0.001
Number of Psychiatric
Diagnosis Groups
0.12 0.12 0.12 0.21 0.15 0.15 0.12 0.11 0.12 0.11 <0.001
MEDICARE
Number of Patients 2303 130 660 53 150 69 434 281 1777 526
Percent of oral cancer group 100.0% 5.6% 28.7% 2.3% 6.5% 3.0% 18.8% 12.2% 77.2% 22.8%
Charlson Comorbidity Index (CCI) 1.88 2.88 1.32 2.45 2.88 2.33 2.13 2.35 2.00 1.49 <0.001
Modified CCIC 0.47 0.53 0.40 0.36 0.52 0.49 0.58 0.54 0.49 0.41 <0.001
Number of Psychiatric 0.06 0.12 0.06 0.11 0.07 0.04 0.04 0.07 0.06 0.07 <0.001
Diagnosis Groups
MEDICAID
Number of Patients 585 52 93 29 70 7 62 68 381 204
Percent of oral cancer group 100.0% 8.9% 15.9% 5.0% 12.0% 1.2% 10.6% 11.6% 65.1% 34.9%
Charlson Comorbidity 2.31 3.15 1.63 3.34 3.20 2.86 1.95 2.18 2.43 2.07 <0.001
Index (CCI)
Modified CCIC 0.59 0.50 0.70 0.62 0.80 0.57 0.82 0.62 0.69 0.41 <0.001
Number of Psychiatric
Diagnosis Groups
0.50 0.62 0.56 0.31 0.59 0.86 0.50 0.54 0.55 0.43 0.536
A. Total known modalities is the sum of previous 7 columns (radiation through surgery + radiation + chemotherapy.
B. P-value is from chi square test for a significant difference between the treatment modalities (including unknown modality).




































Figure 3 Health care costs of single versus multimodal cancer treatment. Notes: For sample with 1 year of follow-up. Medical and drug
expenditures were adjusted to 2009 dollars using Medical Care CPI. The p-value is from a test of statistically significant differences between OC/
OP/SG cancer patients who were treated with a single modality and those treated with multiple modalities.
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after the index diagnosis was 48.3 days, with most days
incurred in the first six months after diagnosis. Indirect
costs associated with STD were significantly higher for
employees with OC/OP/SG cancer than employees with-
out OC/OP/SG cancer – patients with OC/OP/SG cancer
had $17,876 in STD costs compared to $6,916 for the
matched comparison group in the year after the index date
(p< 0.01) (Table 5).
Discussion
The objective of this study was to determine the direct and
indirect costs of OC/OP/SG cancer among cohorts of indi-
viduals in three payer groups: Commercially-insured
enrollees and enrollees with Medicare and supplemental
benefits from their employer, and a Medicaid population.
Analysis of the Commercially-insured individuals revealed
that the average medical costs of OC/OP/SG cancers in
the first year after diagnosis was $79,151, which is signifi-
cantly higher than the cost to treat other cancers ($31,559-
$65,123) [26,27]. Furthermore, individuals who received
surgery, radiation and chemotherapy averaged $153,892
during the year after diagnosis (Commercial sample).
These medical costs are about twice any other reported
cancer costs. These results are not surprising given the
multiple modalities of treatment driven by the significant
number of late or later stage diagnoses. What is unex-
pected is the magnitude of the total cost of cancer treat-
ment. We found that the direct medical costs of OC/OP/
SG cancer were substantially higher for all groups than the
matched comparison group. For the commercial sample,
total annual health care spending was $71,732 more than
the comparison group while Medicare had total annual
health care spending $35,890 higher than their matchedcomparison groups. Patients receiving both surgery and
radiation treatment had the highest costs among the
patients with OC/OP/SG cancer. For those individuals that
survived the first year, indirect costs of short-term disabil-
ity (STD) were also high and approximately double
($7,386 higher) for employees with OC/OP/SG cancer
than for employees in the comparison group.
Further, it is not surprising to learn that the costs of care
for cancer survivors did not return to baseline (before
index date) after the first 6 months to 1 year. Post treat-
ment cancer surveillance by physical examination and
radiographic imaging is routine for several years after ther-
apy is completed in order to detect recurrences early and
when curative salvage therapy is still possible. Late effects
from treatment are frequent and require ongoing manage-
ment. Potential costs include physical and lymphedema
therapy, swallow and voice therapy, dental care, nutritional
support for those with a feeding tube, tracheostomy care
expenses for those who have undergone laryngectomy,
audiometric evaluation and treatment of hearing disorders
resulting from treatment, and increased pharmacologic
costs. Additional studies are needed to quantify the costs
of surveillance and late treatment effects.
Our estimates of the expenditures for individuals with
OC/OP/SG cancer are similar or higher than estimates
reported in the literature. However, previous studies
focused only on squamous cell carcinomas [3,5] and/or
included the broader category of head and neck cancers
[20,28,29]. The cost burden for patients with head and
neck cancer has been observed to depend on patient and
treatment related factors including: stage of disease at diag-
nosis, the treatment regimen, and the occurrence of high
cost side effects [3,5,30]. While approximately 90% of
patients with oral cancer have squamous cell cancer [20],




Known Treatment Modalities Unknown P-












Number of enrollees 3,918 233 882 77 361 55 670 681 2959 959
Total $ 79,151 105,422 32,476 79,072 137,315 137,277 110,679 153,892 99,822 15,373 <0.001
(86,170) (82,487) (47,082) (72,498) (77,676) (125,408) (75,189) (92,759) (88,715) (25,828)
Rx Drug $ 3,541 3,900 2,207 7,858 5,637 8,862 3,602 5,079 4,006 2,107 <0.001
(5,487) (4,484) (3,725) (11,149) (6,560) (14,613) (4,883) (6,628) (5,996) (3,061)
ER $ 723 1,614 330 637 1,641 495 1,035 805 871 265 <0.001
(4,282) (6,465) (1,679) (1,624) (9,247) (1,127) (5,063) (3,571) (4,854) (1,403)
Inpatient $ 20,691 18,778 15,950 20,623 24,166 51,659 28,778 38,334 26,017 4,257 <0.001
(44,150) (43,736) (38,519) (31,899) (43,557) (95,505) (44,889) (60,405) (48,933) (14,789)
Outpatient $ 54,197 81,130 13,989 49,954 105,871 76,260 77,264 109,674 68,927 8,745 <0.001
(60,854) (61,492) (16,468) (52,256) (58,144) (84,987) (54,602) (57,678) (62,582) (17,619)
MEDICARE
Number of enrollees 2,303 130 660 53 150 69 434 281 1777 526
Total $ 48,410 66,670 28,138 57,590 85,462 53,526 67,020 96,520 57,969 16,113 <0.001
(61,599) (59,605) (47,551) (72,809) (72,710) (48,819) (61,044) (79,430) (65,926) (24,099)
Rx Drug $ 3,798 4,362 3,232 6,056 4,332 6,400 3,622 5,102 4,006 3,096 <0.001
(4,558) (5,284) (3,249) (5,723) (4,428) (6,749) (3,918) (4,932) (4,323) (5,220)
ER $ 259 396 175 729 461 294 232 423 289 157 <0.001
(898) (966) (453) (1,868) (983) (574) (1,270) (1,160) (981) (517)
Inpatient $ 12,863 10,860 12,240 15,576 15,527 12,597 17,417 20,164 15,047 5,483 <0.001
(29,872) (24,140) (31,434) (42,028) (34,848) (16,582) (32,743) (35,304) (32,264) (17,905)
Outpatient $ 31,490 51,051 12,492 35,230 65,141 34,235 45,750 70,831 38,627 7,378 <0.001
(43,870) (45,289) (25,229) (46,680) (51,534) (40,263) (42,711) (59,425) (47,302) (10,725)
MEDICAID
Number of enrollees 585 52 93 29 70 7 62 68 381 204
Total $ 59,404 73,861 49,526 37,556 114,761 152,220 68,332 107,287 79,178 22,474 <0.001
(74,919) (79,958) (76,721) (50,914) (108,040) (126,234) (57,119) (59,904) (82,735)
Rx Drug $ 5,254 4,612 4,063 4,936 12,224 19,478 4,306 6,159 6,401 3,113 <0.001



















Table 4 Mean and standard deviation of payments, by treatment modality (Continued)
ER $ 1,119 584 784 537 820 663 480 864 707 1,889 <0.001
(11,530) (1,021) (1,491) (1,045) (1,389) (855) (748) (1,697) (1,318)
Inpatient $ 28,954 38,564 35,280 13,464 50,024 111,605 28,326 45,878 38,939 10,305 <0.001
(62,084) (71,797) (72,032) (38,892) (101,144) (122,921) (51,091) (54,231) (72,752)
Outpatient $ 24,078 30,101 9,399 18,620 51,694 20,474 35,220 54,386 33,132 7,168 <0.001
(28,650) (20,080) (7,624) (20,389) (35,506) (13,681) (24,433) (36,987) (31,159)
A. Total known modalities is the sum of previous 7 columns (radiation through surgery + radiation + chemotherapy.




















Figure 4 Trend in Total Healthcare Costs for Patients with OC/OP/SG Cancer, Commercial Coverage.
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including salivary gland cancer, the average costs may have
been lowered.
Our estimate of the cost of Commercially-insured indivi-
duals with OC/OP/SG cancer during the year after the
index date ($79,151) was very similar to a previous study
that found mean medical care costs of $80,070 (adjusted to
2009 USD$) for patients with squamous cell carcinoma of
the oral/pharyngeal cavity who did not die in the first year
after diagnosis (patients treated at a university hospital or
clinic) [3]. Our estimate of Medicare costs for OC/OP/SG
cancers ($48,410) was higher than found in previous studies
($22,321 [30] - $24,706 [29] in 2009$), although these stud-
ies examined the broader category of head and neck cancer.Figure 5 Trend in Total Healthcare Costs for Patients with OC/OP/SGThere are two previous studies that report costs by treat-
ment modality. The first, a Medicaid study [4] reported
median costs of $27,020 for patients with treatment of pre-
sumed early-stage cancer, and $32,991 for patients with
treatment of presumed late-stage cancer (2009 USD$). We
found similar estimates for median costs in these data
(medians not reported in the tables) that ranged from
$28,820 (surgery only) to $74,579 (radiation only) for those
with treatment.
The second study reported costs during the first
6 months after diagnoses for patients aged 35 and older
with commercial insurance or Medicare with advanced
squamous cell carcinoma of the head and neck [5]. The
study reported $60,551 (radiotherapy alone) and $97,440Cancer, Medicare Coverage.
Figure 6 Trend in Total Healthcare Costs for Patients with OC/OP/SG Cancer, Medicaid Coverage.
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http://www.headandneckoncology.org/content/4/1/15(chemoradiotherapy) total health care costs during the
6 months after diagnosis (all in 2009$). Six month costs
in our study were comparable. For the Medicare sample,
6-month costs were $52,168 (N= 165) for patients with
radiotherapy alone and $66,670 (N= 130) for chemora-
diotherapy. In the Commercial sample, 6 month costs
were $105,422 (N= 233) for radiotherapy alone and
$137,315 (N= 361) for chemoradiotherapy.
It is worth noting that we found evidence of survivor-
ship bias in this study; patients who were followed a
longer period of time post-treatment had lower 6 month
and annual costs. We cannot test survivorship directly
since death is not well captured in administrative claims
data (only in-hospital deaths can be measured). However,
previous studies have reported a survivorship bias largerTable 5 Short Term Disability 1 year after index date for OC/O





Short-Term Disability (STD) Data
Patients with any STD 125
Number of days of STD among all eligible patientsC 48.3
Number of days of STD among patients with any STDD 108.7
Cost among all eligible patientsE $7,952
Cost among patients with any STDE $17,876
For sample with 1 year of follow-up.
Notes
A. Cost burden is the difference between mean costs for O/P cancer patients and th
B. P-value from test of the significance of the difference between patients with O/P
C: All eligible patients are those found in the STD database. Patients may have had 0
D: Patients with any STD are all patients with at least one STD day.
E: STD payments were imputed by an hourly rate of $29.37, value each STD day at 7than that seen in our data; in one study patients who
died in the first year after diagnosis had on average
$50,000 higher costs than patients who did not die in the
first year [3]. This suggests that some, but not all, of our
loss to follow-up is due to death of a patient.
There are a number of limitations to these analyses.
First, individuals with OC/OP/SG cancer were identified
using ICD-9-CM diagnosis codes, which can be less pre-
cise than medical records or other clinical sources. When
an individual did not have an inpatient claim with an OC/
OP/SG cancer diagnosis, the patient was required to have
at least two outpatient claims a minimum of 30 days apart,
thus minimizing the inclusion of patients with “rule-out”
diagnoses. However, it is not uncommon for the diagnostic








%/STD DEV COUNT/MEAN %/STD DEV Diff P-valueB
44.5% 23 8.2% 36.3% <0.0001
88.5 3.4 16.9 44.9 <0.0001
105.3 42.0 44.0 66.6 <0.0001
$14,563 $566 $2,779 $7,386 <0.0001
$17,322 $6,916 $7,240 $10,960 <0.0001
eir matched comparison group.
cancer and their matched comparison group.
days of STD.
0% compensation (e.g., STD Payment = STD days* 0.7*29.37*8).
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tially result in a failure to capture cases.
We captured a large number of patients who did not
have primary surgery or radiation. We examined the
claims for this cohort and it appeared these patients
received diagnosis-related care and not relevant surgery or
radiation for OC/OP/SG cancer. Thus, the cohort may
represent patients who underwent a lengthy and costly
process to rule-out OC/OP/SG cancer and were eventually
diagnosed as having benign disease. The inclusion of
patients who may not have a cancer diagnosis may bias
our estimate of the cost burden downward, creating a
more conservative estimate. A second possibility is that
our list of codes missed some treatments for OC/OP/SG
cancer. It should be noted that a small share of patients
without radiation or surgery did receive chemotherapy.
This may represent a cohort of patients with metastatic
disease who were treated with chemotherapy alone. It is
also possible that a small number of patients may have had
such late-stage cancer that hospice care was selected, ra-
ther than curative treatment. Finally, the radiation codes in
our study are not site-specific and thus could represent ra-
diation treatment on any part of the body.
While the indirect costs were substantial, our study
used only short-term disability (STD) costs in estimating
productivity burden, potentially resulting in an under-
estimation of these costs. We were not able to calculate
indirect costs from absenteeism due to small sample size
and did not capture information about lost productivity
while at work due to OC/OP/SG cancer (presenteeism).
We did not have estimates of the wages and benefits
paid to employees on leave and valued a missed work
day based on the typical benefits (70%) paid to the typ-
ical worker in the U.S. Patients with OC/OP/SG cancer
tend to be older (average age in the Commercial sample
was 53.4 years) than the typical worker. Older workers
with more experience may be paid more than the typical
U.S. worker, so our estimates of the short-term disability
losses may be low. Patients with more severe OC/OP/
SG cancer may have had to discontinue employment or
may have been eligible for long-term disability (LTD) ra-
ther than STD, which would also add to the indirect
costs. These indirect cost estimates must be interpreted
with caution, given the small, non-random sample of
patients with STD data. However, the limited data did
reveal a significant cost burden to the employer. In fact,
the average number of missed days of work as measured
by days of STD in individuals with OC/OP/SG cancer
(48.3 days) was greater than reports of all other cancers
(44 days) [26] Side effects of cancer and its treatment
cannot be over looked as important factors in managing
working patients with cancer. A flexible workplace
schedule is needed for those receiving radiation and/or
chemotherapy. The side effects of fatigue, nausea, andvomiting may require the individual to limit the number
of hours they can work.
Finally, the advantage of our matching approach is that
we provide a reference for what the spending might have
been for patients with OC/OP/SG if they did not have can-
cer, conditional on the characteristics used for matching.
Thus we can account for the fact that OC/OP/SG cancer
is not randomly distributed in the population. However,
the ability to match is limited by what is observable in
medical claims data. We believe our approach to selecting
the reference group is conservative in the sense that it
would lead to decreased cost differences between the OC/
OP/SG cancer group and comparison groups because we
match on health status characteristics at baseline as well as
demographic characteristics. It is likely that we are finding
a sicker and more costly comparison group than if we had
simply matched on age and gender.
Conclusion
This is the first retrospective data analysis of a large
number of head and neck cancer patients in the U.S.
analyzing direct and indirect costs, and comparing those
costs to a matched comparison group., The overall cost
burden of OC/OP/SG cancer is significant and is experi-
enced by all payers, Medicare, Medicaid, the employer,
and the individual. Both the direct costs and the indirect
costs of OC/OP/SG cancer are high. In addition, patients
treated with multiple modalities simultaneously are faced
with some of the highest costs. The results of this ana-
lysis suggest that the treatment costs for OC/OP/SG
may be the highest of all cancers in the U.S. Due to the
fact that multi-modality treatment is more common for
patients with late-stage OC/OP/SG cancer, early detec-
tion to find patients in earlier, less costly, stages of the
disease is important. Having an estimate of the cost bur-
den will help in determining the value of some of the
new tools and improved methods available for early can-
cer detection that could be offered in employee medical
and dental plans and/or employee wellness programs.
Additionally, given the cost burden to both employer
and employees, tobacco cessation programs and smoking
bans should be reviewed. Lastly, the changing pattern of
oral pharyngeal cancer dictates that further studies are
needed to understand the influence of HPV on cancer in
the workplace.
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